An interventional study of Valacyclovir hydrochloride in Herpes Simplex and HIV Infections, sponsored by Glaxo Wellcome. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-01-29.
Sponsored by Glaxo Wellcome · Not applicable, Interventional, and Treatment
The purpose of this study is to see if valacyclovir affects the detection of HIV in genital herpes lesions in HIV-infected patients. Valacyclovir is used to treat recurrent genital herpes.
Following evaluation for 2 consecutive episodes of genital herpes in this double-blind, crossover study, 30 HIV-1 positive patients are randomized to receive either valacyclovir or placebo.
All patients are treated for 10 days.
305 studies on the registry are indexed under Herpes Simplex; 31 are open to participants now.
This study's enrollment of 30 is below the median of 101 across 227 interventional studies indexed under Herpes Simplex.
Browse Herpes Simplex studies →Glaxo Wellcome is the lead sponsor of 72 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients must have:
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
Patients with the following prior conditions are excluded:
History of hypersensitivity to acyclovir or valacyclovir.
Prior Medication:
Excluded:
Systemic anti-HSV therapy within 7 days prior to start of study drug.
Required:
No study locations are listed for this record.
This study is completed, as verified in Jun 1999. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Glaxo Wellcome